Publications

Hogan Lovells Publications

The importance of conscientious health data collection in European clinical trials

Clinical trials have become increasingly important for pharmaceutical companies and medical device manufacturers, which are focused on collecting as much data as possible on products and...

Hogan Lovells Publications

Highlights from the DigiHealth Leaders Conference: interoperability, reimbursement, patient centricity, and forging effective partnerships

Digital health offers huge potential for improving care and alleviating the increasing burden on our over-stretched healthcare systems. However, its uptake remains slow and varies...

Hogan Lovells Publications

DHSC Update on Medicines and Medical Devices Contingency Planning

Following the recent agreement to delay Brexit until 31 January 2020, the UK Department of Health and Social Care (DHSC) has written to suppliers of UK medicines and medical devices to...

Hogan Lovells Publications

A bit more Sunshine: CMS proposes collecting additional information on manufacturer payments under the Open Payments program Health Alert

Device and drug manufacturers got a small surprise in the annual Physician Fee Schedule proposed rule (at 40,713-16) issued late in July by the Centers for Medicare & Medicaid Services...

News

Influencer Promo Guide: Best Practices for Drug and Device Firms

In our “Influencer promo guide: Best practices for drug and device firms”, we offered a list of best practices for medical device and pharmaceutical companies interested in...

Hogan Lovells Publications

An intelligent approach for regulating medical device AI Medical Device Alert

Hogan Lovells has been at the forefront of advising our clients on the clearance or approval of an increasing number of software as a medical device (SaMD) products and other medical...

Loading data